Could a Once-Daily pill cut deadly clots in cancer patients?
NCT ID NCT07005024
First seen Feb 05, 2026 · Last updated Apr 28, 2026 · Updated 10 times
Summary
This study tests whether a common blood thinner (apixaban) can safely prevent dangerous blood clots in cancer patients at moderate risk. About 996 adults with solid tumors or lymphoma will receive either a standard twice-daily dose, a simpler once-daily dose, or no blood thinner for 6 months. Researchers will compare how many develop clots, serious bleeding, or die, aiming to find a more convenient prevention strategy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Vermont Medical Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.